Subscribe
dra_schwartz
13 December 2018Big Pharma

Biotech firm to use Merck’s CRISPR patents in rodent models

France-based biotechnology company genOway has acquired the exclusive global rights to German pharmaceutical company Merck Group’s CRISPR patents, to be used in the production and sale of rodent models.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
The new IP battleground in CRISPR-Cas
21 November 2023   Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.
Americas
Buyers of Zetia seek class recertification after 4th circ ruling
28 September 2021   Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.
Americas
Merck signs DNA licensing deal with Vertex
28 January 2019   German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases inhibitors.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Biotechnology
The new IP battleground in CRISPR-Cas
21 November 2023   Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.
Americas
Buyers of Zetia seek class recertification after 4th circ ruling
28 September 2021   Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.
Americas
Merck signs DNA licensing deal with Vertex
28 January 2019   German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases inhibitors.

More on this story

Biotechnology
The new IP battleground in CRISPR-Cas
21 November 2023   Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.
Americas
Buyers of Zetia seek class recertification after 4th circ ruling
28 September 2021   Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.
Americas
Merck signs DNA licensing deal with Vertex
28 January 2019   German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases inhibitors.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims